PimedBio Signs MOU with K-MEDI Hub 

for CDMO Services and Drug Development

— Strategic Partnership to Accelerate Clinical Supply and Global Expansion —

PimedBio is pleased to announce that it has signed a Memorandum of Understanding (MOU) with the Korea Daegu-Gyeongbuk Medical Innovation Foundation (K-MEDI Hub), led by Chairman Yang Jin-young, to collaborate on the Contract Development and Manufacturing (CDMO) of its innovative anti-cancer therapeutics.

•   Date: February 8, 2022, at 11:00 AM (KST)

•   Location: PimedBio Conference Room

 This agreement follows a successful joint research project conducted last year, during which PimedBio and K-MEDI Hub’s Clinical Drug Manufacturing Center completed the production of Active Pharmaceutical Ingredients (API) for non-clinical studies.

The two organizations are currently in discussions to expand their collaboration across the entire drug development lifecycle, including:

• Formulation Research & Development

• Production of APIs and Finished Drug Products (FDP)

• Regulatory Affairs (RA) and Licensing support

•  

 Through this partnership, PimedBio plans to utilize investigational medicinal products (IMPs) produced at the K-MEDI Hub facility for upcoming domestic clinical trials. Furthermore, the company aims to leverage this high-quality manufacturing foundation to pursue clinical trials with the U.S. Food and Drug Administration (FDA) in the near future.

 By securing a reliable domestic CDMO partner, PimedBio is well-positioned to stabilize its clinical supply chain and accelerate the development of its "first-in-class" cancer stemness inhibitors. We remain committed to bringing innovative treatments to patients worldwide through strategic technical collaborations.